Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Director
Asklepios Tumorzentrum Hamburg
Department of Oncology
AK Altona
Hamburg, Germany
Associate Professor
Sidney Kimmel Cancer Center
Johns Hopkins University
Director
Clinical Research, GI and Phase I Oncology in the National Capital Region
Johns Hopkins at Sibley Memorial Cancer Center
Washington, DC
Editorial Contributor
Senior Clinical Editor
Associate Director, Scientific Services
Senior Director, Global Medical Education, Europe
Senior Director, Educational Strategy
This program is intended for medical oncologists and other healthcare providers who care for patients with pancreatic cancer globally.
This program has been made available online.
Data from the CONKO-007 trial of chemoradiotherapy vs chemotherapy for locally advanced pancreatic cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers
Experts highlight key studies being presented at the 2022 ASCO Annual Meeting in this commentary from Clinical Care Options (CCO)
From Clinical Care Options (CCO), downloadable PDF featuring key points from expert discussion on PARP inhibitors in treatment of pancreatic cancer
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.